Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative 'decoy' receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIP L but not c-FLIP S . Both caspase-8 and c-FLIP L were cleaved to form two stable intermediates of *43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIP L to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.
Introduction
B-cell chronic lymphocytic leukaemia (B-CLL), one of the most common haematological malignancies in the western world, is characterized by the accumulation of mature non-proliferating B cells that co-express CD5 and CD23 (Rozman and Montserrat, 1995) . This accumulation results from a failure of cells to undergo apoptosis rather than by excessive cellular proliferation.
Several members of the tumour necrosis factor (TNF) family induce apoptosis. Induction of apoptosis is restricted to receptors that contain a protein -protein interaction motif, termed the 'death domain', and include those activated by CD95/FasL and TNFrelated apoptosis-inducing ligand (TRAIL). Intracellular molecules that couple CD95 to the apoptotic pathway include the adaptor molecule FADD/MORT1 (Chinnaiyan et al., 1995; Kischkel et al., 1995) , which recruits caspase-8 into the death-inducing signalling complex (DISC) (Boldin et al., 1996; Muzio et al., 1996) . Similarly, TRAIL engages apoptosis via recruitment and rapid activation of caspase-8 (MacFarlane et al., 2000) , which may in some cases be independent of FADD (Yeh et al., 1998) . However, recent studies demonstrate both FADD and caspase-8 are integral components of the TRAIL DISC (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) . Importantly, TRAIL induces apoptosis in a wide range of tumour cell lines but not in most normal cells (Wiley et al., 1995; Marsters et al., 1996) . TRAIL interacts with four distinct membrane-bound receptors: TRAIL-R1 (DR4), TRAIL-R2 (DR5/TRICK2), TRAIL-R3 (TRID/DcR1/LIT) and TRAIL-R4 (DcR2/TRUNDD) (reviewed in Ashkenazi and Dixit, 1998) . TRAIL-R1 and TRAIL-R2 are death receptors and contain the cytoplasmic 'death domain' necessary to mediate apoptosis. TRAIL-R3 and TRAIL-R4 lack or contain a truncated death domain and consequently do not mediate apoptosis and have been proposed to inhibit TRAIL-induced apoptosis either by acting as decoy receptors or via transduction of an anti-apoptotic signal. TRAIL-and CD95-induced apoptosis is also regulated by inhibitory molecules, which interfere with signalling from the DISC. Such molecules include cellular Flice inhibitory protein (c-FLIP), which competes with caspase-8 for binding to FADD (Scaffidi et al., 1999) , and cIAP-1 and -2 that can be induced by NF-kB and may act to inhibit caspase-8 (Wang et al., 1998) . c-FLIP is structurally similar to caspase-8, containing two death effector domains and a caspaselike domain, which lacks the active-site cysteine of caspase-8 (Irmler et al., 1997; Scaffidi et al., 1999) . Two endogenous forms are present, c-FLIP L and c-FLIP S ; both are recruited to the CD95 DISC and inhibit CD95-induced apoptosis (Irmler et al., 1997; Scaffidi et al., 1999; Krueger et al., 2001) . Activation of normal human B cells up-regulates c-FLIP expression and delays apoptosis in CD95-sensitive B cells, suggesting that c-FLIP may prevent inappropriate cell death (Hennino et al., 2000) .
Exploitation of receptor-mediated apoptosis may represent a novel therapeutic strategy for many forms of cancer, although the use of TNF or CD95 has been prohibited by their toxicity toward normal tissues. In contrast, TRAIL may represent a more suitable ligand for exploitation, as it does not generally induce cell death in normal tissues. B-CLL and other B cell malignancies, such as B-cell non-Hodgkin's lymphoma (B-NHL), are commonly resistant to CD95-mediated apoptosis (Wang et al., 1997; Xerri et al., 1997; Plumas et al., 1998) . The mechanism(s) of CD95 resistance in these cells is unclear, but may include lack of expression of functional receptors or overexpression of inhibitory molecules.
Results

Resistance of B-CLL cells to receptor-mediated apoptosis
Primary B-CLL cells from patients were generally not sensitive to either TRAIL or anti-CD95, whereas three tumour cell lines were sensitive ( Figure 1 and Table  1 ). Even at higher concentrations of TRAIL (2000 ng/ ml), B-CLL cells were resistant to apoptosis. Control and TRAIL-induced apoptosis in B-CLL cells were 21+12 and 22+11%, respectively (mean+s.e. from three different patients). However, extensive apoptosis was observed in Jurkat cells exposed to TRAIL (100 ng/ml), a 20-fold lower concentration ( Figure  1 ). As there has been some controversy over the form of TRAIL used to induce apoptosis (Lawrence et al., 2001) , we also used a commercially available form, TRAIL Biomol. B-CLL cells were also resistant to this form of TRAIL (2000 ng/ml). In contrast, B-CLL cells were sensitive to apoptosis induced by the proteasome inhibitor MG132 as assessed by increased externalization of phosphatidylserine (PS) (Figure 1a ) and caspase activation (Almond et al., 2001) , which confirmed that the effector arm of apoptosis was present and operational in these cells. These results demonstrated that B-CLL cells were resistant to TRAIL and raised the possibility that this may be due to a defect in cell surface expression of TRAIL receptors.
Cell surface expression of TRAIL receptors
In the tumour cell lines, two patterns of cell surface death receptor expression were observed: in Jurkat cells TRAIL-R24TRAIL-R144TRAIL-R4 whereas in both SKW and MC116 cells TRAIL-R15TRAIL-R24TRAIL-R4 (Figure 2) . No cell surface expression of TRAIL-R3 was detected in any of the cell lines (Figure 2 ). In B-CLL cells, lower levels of TRAIL Figure 1 Primary B-CLL cells are resistant to TRAIL-induced apoptosis. (a) Freshly isolated B-CLL cells were incubated in the presence of LZ-TRAIL (500 ng/ml; case 5 is shown) or the proteasome inhibitor MG132 (1 mM) for 24 h. Cell death was quantified by flow cytometric analysis after staining with Annexin V-FITC/propidium iodide (PI), and the percentage of cells with increased PS exposure is indicated. (b) Cell lines were incubated with LZ-TRAIL (100 ng/ml) for 6 h, and apoptosis assessed by PS externalization. (Figure 2 ). Thus the resistance of the B-CLL cells to TRAIL-induced apoptosis was not probably due to increased cell surface expression of 'decoy' receptors in agreement with other studies (Griffith et al., 1998; Leverkus et al., 2000) .
Both FADD and caspase-8 are expressed in B-CLL cells FADD was detected as two immunoreactive products of *28 kDa, most probably corresponding to different phosphorylated forms of FADD observed in both human and mouse cells (Kischkel et al., 1995; Zhang and Winoto, 1996) . Lower levels of FADD were detected in B-CLL cells compared to the cell lines (Figure 3 ). Significant levels of caspase-8 were observed in all B-CLL samples and in the cell lines. In all B-CLL samples, caspase-8 was detected as a doublet of *55 kDa (Figure 3 ), possibly corresponding to the two isoforms, caspases-8a and -8b (Scaffidi et al., 1997) . When equivalent numbers of cells from the patients or cell lines were examined, either by Ponceau S staining (data not shown) or immunoblotting for the housekeeping protein GAPDH (Figure 3 ), a greater cellular protein content was observed in the cell lines, which correlated with their larger cell diameter (12.5 mm) compared to B-CLL cells (7.5 mm). Thus, based on loading of equivalent cell numbers, more FADD and caspase-8 were clearly evident in the transformed cell lines Freshly isolated B-CLL cells were incubated in vitro in the presence of LZ-TRAIL (500 ng/ml) or anti-CD95 (500 ng/ml) for 24 h. Apoptosis in control and treated samples was determined by Annexin V binding. The white blood count (WBC) and Binet stage of each patient is indicated, together with the sex and age of each patient.
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Resistance of B-CLL cells to TRAIL-induced apoptosis M MacFarlane et al compared to the B-CLL cells but this merely reflected the difference in cell size. Thus in B-CLL cells both FADD and caspase-8 were present in sufficient amounts to engage apoptosis by the death receptor machinery.
The inhibitory molecules c-FLIP and XIAP are expressed in B-CLL cells
In order to explain the resistance of B-CLL cells to TRAIL, the expression of c-FLIP and XIAP was examined. c-FLIP was detected in all clinical samples, migrating as two isoforms of *55 and *28 kDa ( Figure  3 ), corresponding to c-FLIP L and c-FLIP S (Irmler et al., 1997; Scaffidi et al., 1999) . Expression of the two isoforms was approximately equal. The anti-apoptotic mechanisms of some IAP proteins are unknown although XIAP, cIAP-1 and cIAP-2 appear to inhibit both stress-and death receptor-induced apoptosis through direct inhibition of distinct caspases (reviewed in . In B-CLL cells and the cell lines, XIAP was detected as a band of *57 kDa together with a previously reported non-specific immunoreactive product of *58 kDa ( Figure 3 ). In order to determine whether FLIP and XIAP were involved in TRAIL resistance, B-CLL cells were treated with inhibitors of transcription and translation, which increase the sensitivity of certain target cells that are otherwise resistant to CD95L, TNF or TRAIL-induced apoptosis (Griffith et al., 1998; Mori et al., 1999; Leverkus et al., 2000) . 
Bisindolylmaleimides do not alter c-FLIP levels or sensitize B-CLL cells to TRAIL-induced apoptosis
In order to better understand the regulation of c-FLIP L in B-CLL cells and to exclude its role in resistance, cells were pre-treated with bisindolymaleimide derivatives, which can sensitize tumour cells, T lymphocytes and dendritic cells to CD95 by decreasing c-FLIP expression (Zhou et al., 1999; Willems et al., 2000) . B-CLL cells were pre-treated with two concentrations of each bisindolylmaleimide, one sub-toxic and the other displaying low toxicity, and then exposed to TRAIL (Figure 5a ). Higher concentrations of all three bisindolylmaleimides induced apoptosis (data not shown). No increase in TRAIL sensitivity was observed following pre-treatment with the bisindolylmaleimides (Figure 5a ). In addition no significant decrease in c-FLIP L or c-FLIP S or XIAP levels was observed except with bisindolylmaleimide III (10 mM), where a small decrease in c-FLIP L (Figure 5b ) reflected a small induction of apoptosis. Thus, bisindolylmaleimide derivatives neither decreased c-FLIP levels nor sensitized B-CLL cells to TRAIL. Taken together with the cycloheximide data, these results suggest that the regulation of c-FLIP in B-CLL cells is different from many other cell types studied. 
TRAIL does not induce processing of caspase-8 in B-CLL cells
In order to test whether the resistance of B-CLL cells to TRAIL-induced apoptosis was due to their inability to process caspase-8, we examined B-CLL cells exposed to TRAIL. No processing of caspase-8 was observed using two different forms of TRAIL (500 -2000 ng/ml), whereas Jurkat cells exposed to TRAIL (100 ng/ml) showed extensive processing ( Figure 6 ). In the Jurkat cells, caspase-8 was processed both to its p43 and p41 forms, which arise following cleavage of caspases-8a and -8b between their large and small subunits, and also to its p18 catalytically active large subunit in agreement with our earlier studies (Sun et al., 1999) . These results demonstrated that the resistance of B-CLL cells to TRAIL-induced apoptosis was upstream of their ability to process caspase-8.
TRAIL induces a DISC in B-CLL cells
As the resistance to TRAIL occurred prior to caspase-8 activation, it was possibly due to the inability of the B-CLL cells to form a functional DISC. As a positive control we used Jurkat T cells, which are sensitive to TRAIL (Figure 1b) and form a DISC with recruitment of caspase-8 and FADD (Bodmer et al., 2000; Sprick et al., 2000) . TRAIL induced the formation of a DISC in Jurkat cells together with the recruitment of FADD and caspase-8 ( Figure 7, lane 3) . Within the DISC, caspase-8 was also processed both to its p43 and p41 forms and also to its p18 catalytically active large subunit ( Figure The association of FADD and caspase-8 were both TRAIL stimulation-dependent since they were not recruited when biotinylated-TRAIL was added after cell lysis, whereas the non-stimulated TRAIL-R2 was precipitated ( Figure 7 , lane 5). Interestingly, in B-CLL cells, caspase-8 was recruited to the DISC and was present both as p55 and p53 unprocessed zymogens corresponding to caspases-8a and -8b, as well as their partially processed forms of p43 and p41 but without any detectable p18 large subunit (Figure 7 , lanes 6 and 7). Thus, partially processed caspase-8 was detected within the DISC (Figure 7 ), but not in B-CLL cells treated with TRAIL (Figure 6 ), most probably due to the increased sensitivity provided by analysing the trimerised death receptors and associated proteins within the DISC. It was also possible that some of the resistance to TRAIL was due to c-FLIP L and c-FLIP S , both of which are expressed in B-CLL cells (Figure 3 ). These molecules are recruited to the DISC and inhibit CD95-induced apoptosis (Scaffidi et al., 1999; Kirchoff et al., 2000; Krueger et al., 2001) . Following TRAIL stimulation of B-CLL cells, c-FLIP L but not c-FLIP S was recruited to the DISC (Figure 7) . Interestingly, in the stimulated but not the unstimulated cells, most of the c-FLIP L was cleaved to an *p43 fragment ( Figure  7 , lanes 6 and 7), which most likely represents the product obtained following removal of its C-terminal p10 subunit (Scaffidi et al., 1999) . Recruitment of c-FLIP L to the DISC might also contribute to the resistance of B-CLL cells to TRAIL.
Discussion
TRAIL has recently emerged as a novel anti-cancer agent, based on its induction of cell death in many tumour cell lines and its lack of toxicity to most normal cells Walczak et al., 1999) . TRAIL may be toxic to normal human (Jo et al., 2000) although its in vivo toxicity remains to be established. Importantly, the in vitro sensitivity of normal primary astrocytes to LZ-TRAIL was not observed in vivo (Walczak et al., 1999) . In order to assess the value of TRAIL, we have determined its toxicity to primary B-CLL cells from patients as opposed to the use of cell lines, which have been used in most other studies. B-CLL cells were resistant to TRAIL and CD95 (Table 1) in accord with other studies (Xerri et al., 1997 (Xerri et al., , 1998 Wang et al., 1997; Plumas et al., 1998) . Thus, in vitro resistance to TRAIL may be common to many primary haematological malignancies (Snell et al., 1997) . This resistance was likely mediated through inhibition of the initiation of apoptosis from the death receptor as little or no processing of the initiator caspase-8 was observed in B-CLL cells exposed to TRAIL (Figure 6 ). In addition effector caspase activity appeared normal, as these same cells were susceptible to chemically induced apoptosis (Figure 1 ) with concomitant processing of caspases-3 and -7 (Almond et al., 2001) . Although many studies show potentiation of CD95 or TRAIL-induced apoptosis in the presence of cycloheximide or actinomycin D, few of these have investigated the mechanism. In some cell types, there is undoubtedly a correlation of decreased FLIP levels with increased TRAIL sensitivity (Griffith et al., 1998; Leverkus et al., 2000; Fulda et al., 2000; Munshi et al., 2001) . However in other cell types, including thyroid cells, Kaposi sarcoma cells and human prostate epithelial cells, cycloheximide or actinomycin D potentiates TRAIL-induced apoptosis without altering c-FLIP levels (Mori et al., 1999; Ahmad and Shi, 2000; Nesterov et al., 2002 ). An important finding in our study in B-CLL cells was that cycloheximide potentiated TRAIL-induced apoptosis without alteration of c-FLIP levels. Thus the ability of cycloheximide to potentiate TRAIL-induced apoptosis appears to be dependent in part on cell-type as well as on other uncharacterized factors. c-FLIP expression in B-CLL cells was also unchanged following treatment with bisindolylmaleimides, despite their ability to lower c-FLIP levels in other cell types (Zhou et al., 1999; Willems et al., 2000) . Taken together these data suggest that the regulation of c-FLIP expression in B-CLL cells is different from several other cell types and may present a novel therapeutic target to sensitize these cells to death receptor-induced apoptosis. In addition, cycloheximide-sensitive intracellular inhibitors other than c-FLIP and IAPs must account, in part, for the resistance of these cells to TRAIL. Potential inhibitory proteins include Bcl-2 family members and the silencer of death domain molecule (SODD) (Jiang et al., 1999) . However, other recent reports including one study in B-CLL cells (Snell et al., 1997) have demonstrated that differences in Bcl-2 expression do not always correlate with sensitivity to TRAIL and also appear cell-type dependent (Keogh et al., 2000; Walczak et al., 2000) .
Although low levels of TRAIL-R1 and TRAIL-R2 were expressed on the surface of B-CLL cells, they were sufficient to allow formation of a TRAIL DISC (Figure 7 ). These low levels may partly explain the small amount of DISC formation in B-CLL cells compared to Jurkat cells (*10 times more B-CLL cells were required; Figure 7) , thereby contributing to the resistance of B-CLL cells to TRAIL. In cell lines stably overexpressing c-FLIP L or c-FLIP S , both isoforms are recruited to the DISC but inhibit CD95-induced apoptosis in subtly different ways (Krueger et al., 2001) . The presence of c-FLIP S prevents cleavage of caspase-8, whereas with c-FLIP L the initial processing of caspase-8 to its p43/41 fragments is observed and the cleavage intermediates of both caspase-8 and c-FLIP L remain bound to the receptor, so preventing further recruitment of procaspase-8 to replace the processed caspase-8 at the DISC (Krueger et al., 2001) . The data in B-CLL cells (Figure 7) is compatible with the latter model of c-FLIP L preventing further recruitment of caspase-8 to the DISC. In addition, c-FLIP has a higher affinity for the DISC than caspase-8 and is rapidly recruited to the DISC and readily cleaved (Scaffidi et al., 1999) , in agreement with our current finding that most of the c-FLIP L recruited to the DISC was cleaved to its *p43 fragment (Figure 7) . These results also demonstrate that caspase-8 was initially catalytically active. In B-CLL cells exposed to TRAIL, caspase-8 in the DISC was processed only to its p43 and p41 forms, whereas p43, p41 and p18 forms of caspase-8 were detectable both in the DISC and the lysates of Jurkat cells (Figures 6 and 7) . These results imply that in B-CLL cells the block in caspase-8 7 cells per treatment) or B-CLL cells (3610 8 cells per treatment) were exposed to biotinylated-TRAIL for the indicated times and a DISC isolated as described in Materials and methods. To provide an unstimulated receptor control, biotinylated-TRAIL was added to lysate from untreated cells (u/s). It should be noted that *10-fold the number of B-CLL cells were treated compared to Jurkat cells and the DISCs obtained were analysed by Western blotting using the same concentration of antibodies and similar exposure times. Lysates from unstimulated Jurkat or B-CLL cells (lanes 1 and 4, respectively) were used as positive controls activation occurred within the DISC, where c-FLIP L only allowed initial processing of caspase-8 to its p43 and p41 forms. In addition, the c-FLIP L /caspase-8 ratio is an important determinant of susceptibility to CD95-mediated apoptosis in Epstein-Barr virus transformed cells (Tepper and Seldin, 1999) . Recently we have also suggested that resistance to TRAIL may be due in part to a high c-FLIP/caspase-8 ratio within the DISC (Harper et al., 2001) . In the present study, the ratio of c-FLIP L to caspase-8 was higher in B-CLL compared to Jurkat cells (Figure 7) . Taken together these data support the hypothesis that part of the resistance of B-CLL cells to TRAIL-induced apoptosis is due both to recruitment of c-FLIP L , which prevents further recruitment of caspase-8 to the DISC, and also to the high c-FLIP/caspase-8 ratio within the DISC, which inhibits caspase-8 processing.
Interestingly, although B-CLL cells expressed high levels of both c-FLIP L and c-FLIP S (Figures 3 and 7) , only c-FLIP L was recruited to the TRAIL DISC. As both c-FLIP L and c-FLIP S contain two N-terminal death effector domains, these results suggest that the caspase-like C-terminal domain present in c-FLIP L but not in c-FLIP S is involved in part in efficient recruitment to the DISC.
Resistance to TRAIL may also be due to mutations, such as those of TRAIL-R2 in some forms of cancer (Pai et al., 1998; Lee et al., 1999) . A polymorphic mutation in the death domain of TRAIL-R1 is also present in about 20% of the normal population . Resistance to TRAIL-induced apoptosis in B-CLL cells does not exclude its future use, particularly if the sensitization seen in vitro can be mimicked in vivo. Subtoxic concentrations of chemotherapeutic drugs can sensitize resistant tumour cells by upregulation of death-inducing TRAIL receptors (Pai et al., 1998; Lee et al., 1999; Keane et al., 1999) . Such an approach could lead to a sensitization of B-CLL cells, together with the added benefit of reduced toxicity and a lower risk of developing drug resistance. This approach may be particularly valuable with B-CLL cells because of their low surface expression of death receptors (Figures 2  and 7) .
In summary, we have demonstrated that primary B-CLL cells are resistant to TRAIL. This resistance was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low expression of TRAIL death receptors on the cell surface resulted in the formation of low levels of a TRAIL DISC, which contained FADD, caspase-8 and c-FLIP L . Thus the resistance of B-CLL cells appears to be due in part to low levels of DISC formation and also to the high ratio of c-FLIP L to caspase-8 within the DISC, which would prevent further activation of caspase-8. While our results highlight the possibility of sensitizing B-CLL cells to TRAIL either through upregulation of death receptors or by decreasing c-FLIP levels, the precise mechanism(s) underlying TRAIL resistance in B-CLL cells requires further investigation.
Materials and methods
Patients
Blood samples were obtained from B-CLL patients, staged according to the Binet system, during routine diagnosis at the Leicester Royal Infirmary (UK) with patient consent and local ethical committee approval. Samples were collected into Li-Heparin tubes.
Materials
Media and serum were from Life Technologies, Inc. (Paisley, UK). Anti-CD95 monoclonal antibody (CH-11 clone) was from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Human recombinant TRAIL was from Biomol Research Laboratories (Plymouth Meeting, USA). LZ-TRAIL (a TRAIL-leucine-zipper fusion protein) and the TRAIL-R1-R4 antibodies (clones M271, M413, M430 and M444, respectively) were kind gifts from Immunex Corp., Seattle, WA, USA . The proteasome inhibitor MG132 (carbobenzoxyl-leucinyl-leucinyl-leucinal) was from Calbiochem (La Jolla, CA, USA). Annexin V-FITC was from Bender MedSystems (Vienna, Austria). Bisindolylmaleimides III, VIII and IX were from Alexis Biochemicals (Nottingham, UK). The sensitivity of B-CLL cells to TRAIL-induced apoptosis was compared to sensitive human cell lines, namely Jurkat T cells (clone E6-1) and the B cell Burkitts lymphoma cell line MC116, both obtained from ECACC and the B lymphoblastoid cell line, SKW6.4 (SKW), kindly provided by Dr M Peter (Heidelberg, Germany). Other reagents were from Sigma (Poole, UK).
Lymphocyte purification and culture
Whole blood was layered over Histopaque and B-CLL cells purified as previously described (King et al., 1998; Almond et al., 2001 ) except that T cells were removed using anti-CD3 Dynabeads (Dynal, Merseyside, UK) resulting in a mean average purity of 98.2% CD19 + CD5 + B-CLL cells. The purified B cells were resuspended in RPMI 1640 medium (2610 6 /ml) in 6-well plates at 378C in an atmosphere of 5% CO 2 and incubated for up to 24 h with anti-CD95 (500 ng/ ml), LZ-TRAIL (500 -2000 ng/ml) or MG132 (1 mM). Where indicated, lymphocytes were preincubated for 18 h in the presence or absence of actinomycin D, cycloheximide, or bisindolylmaleimides III, VIII and IX and then incubated with TRAIL (500 ng/ml) for a further 6 -24 h as indicated. Samples were either analysed for apoptosis or pelleted and stored at 7808C for subsequent Western blotting.
Quantification of apoptosis and Western blot analysis
Apoptotic cells were quantified by an increase in externalized phosphatidylserine as assessed by Annexin V labelling (King et al., 1998) . Samples for Western blot analysis were prepared as described (Sun et al., 1999) . Caspase-8, FADD (Transduction Laboratories, Lexington, KY, USA), XIAP (Transduction Laboratories), c-FLIP (Rasper et al., 1998) and GAPDH (Advanced Immunochemical Inc, CA, USA) were detected as described previously (Sun et al., 1999) .
Assessment of cell surface receptor expression
Purified B-CLL cells were resuspended in blocking buffer (10% normal goat serum in PBS) and incubated for 30 min on ice to block non-specific binding, then incubated with 
DISC analysis
DISC precipitation was performed using biotin-tagged recombinant TRAIL (biotinylated-TRAIL) essentially as described (Sprick et al., 2000; Harper et al., 2001) . B-CLL cells (3610 8 cells per treatment) were treated with biotinylated-TRAIL for either 30 or 120 min and DISC formation determined (Harper et al., 2001) . Western blotting was performed using 30 ml of eluted complexes from streptavidin-agarose beads representing DISC precipitated from 3610 8 cells. Jurkat cells (2.5610 7 cells per treatment) were similarly exposed to TRAIL as a positive control for DISC formation.
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